Motor function (observable entity)

MeiraGTx’s Gene Therapy Shows Significant Improvements in Motor Function and Quality of Life in Parkinson’s Disease Trial

6 months ago talkbio0Tagged AAV-GAD, Clinical Trials, dopamine, gamma-aminobutyric acid, gene therapy, MeiraGTx, Motor function (observable entity), Neurodegenerative Disorders, Parkinson 's disease, Phase 2 trial, production, Quality of life, Surgical Replantation

MeiraGTx, Gene Therapy, Parkinson’s Disease, AAV-GAD, Motor Function, Quality of Life, Clinical Trial, Phase 2 Trial, Neurodegenerative Disease, Dopamine Replacement, GABA Production

Biogen’s Higher Dose Spinraza Shows Enhanced Efficacy in Treating Spinal Muscular Atrophy

7 months ago talkbio0Tagged Biogen, Clinical Trials, DEVOTE, Dose Regimen, High, Improvement, Motor function (observable entity), Nerve Degeneration, nusinersen, Spinal Muscular Atrophy, Spinraza

Biogen, Spinraza, Nusinersen, Spinal Muscular Atrophy (SMA), Higher Dose Regimen, Clinical Trial Results, DEVOTE Study, Motor Function Improvement, Neurodegeneration Reduction

Scholar Rock’s Apitegromab Shows Significant Improvement in Spinal Muscular Atrophy Treatment

7 months ago talkbio0Tagged apitegromab, Clinical Trials, GDF8 protein, human, Improvement, Motor function (observable entity), Phase 3, Psychological inhibition, Spinal Muscular Atrophy

Spinal Muscular Atrophy (SMA), Apitegromab, Phase 3 Clinical Trial, Motor Function Improvement, Myostatin Inhibition

Annovis Bio Reports Promising Phase III Study Results for Buntanetap in Parkinson’s Disease Treatment

10 months ago talkbio0Tagged Annovis, Bio, buntanetap, Cognition, MDS-UPDRS, Motor function (observable entity), Neurodegenerative Disorders, Parkinson 's disease, Parkinson 's Disease Rating Scale, Phase 3 Clinical Trials, Unified - Type of Agreement

Annovis Bio, Buntanetap, Parkinson’s Disease, Phase III Study, Neurodegenerative Disorders, Cognitive Function, Motor Functions, Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)